We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
From Aug 2019 to Aug 2024
Bayer AG (BAYN.XE) said Monday it is seeking approval from the U.S. and the E.U. to use its drug Nexavar to treat thyroid cancer.
MAIN FACTS:
-Nexavar, also known as sorafenib, is an oral drug developed and marketed by Bayer HealthCare and Onyx Pharmaceuticals Inc. (ONXX).
-The companies have applied to the U.S. Food & Drug Administration and the European Medicines Agency to use the drug to treat localized, advanced thyroid cancer or metastasis.
-"Especially for patients in the advanced stage, treatment options are lacking or very limited," Bayer's head of global development Dr. Kemal Malik said.
-Nexavar is already approved to treat liver cell cancer and advanced kidney cancer, Bayer said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
